{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T12:02:29Z","timestamp":1789214549445,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473432"],"award-info":[{"award-number":["82473432"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.canlet.2026.218727","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T14:56:30Z","timestamp":1783781790000},"page":"218727","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A novel lncRNA HUDRPC suppresses ferroptosis via the DDX5\/DDIT3 pathway to promote docetaxel resistance in prostate cancer"],"prefix":"10.1016","volume":"657","author":[{"given":"Sudong","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanji","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mierzhayiti","family":"Batuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4295-3937","authenticated-orcid":false,"given":"Qipeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengke","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.canlet.2026.218727_bib1","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"issue":"27","key":"10.1016\/j.canlet.2026.218727_bib2","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1200\/JCO.2010.34.3996","article-title":"Chemotherapy-based treatment for castration-resistant prostate cancer","volume":"29","author":"Seruga","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.canlet.2026.218727_bib3","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218727_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100916","article-title":"Overcoming cancer chemotherapy resistance by the induction of ferroptosis","volume":"66","author":"Wang","year":"2023","journal-title":"Drug Resist. Updates"},{"issue":"6","key":"10.1016\/j.canlet.2026.218727_bib5","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1158\/0008-5472.CAN-20-3477","article-title":"Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer","volume":"81","author":"Ghoochani","year":"2021","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.canlet.2026.218727_bib6","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.eururo.2019.07.040","article-title":"The evolution of long noncoding RNA acceptance in prostate cancer initiation, progression, and its clinical utility in disease management","volume":"76","author":"Ramnarine","year":"2019","journal-title":"Eur. Urol."},{"issue":"11","key":"10.1016\/j.canlet.2026.218727_bib7","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/j.molcel.2026.04.026","article-title":"Hypoxia-driven lncRNA SHIELD promotes GPX4 translation and protects against ferroptosis in hepatocellular carcinoma","volume":"86","author":"Liu","year":"2026","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.canlet.2026.218727_bib8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s11658-024-00560-2","article-title":"Role of ferroptosis and ferroptosis- related long non'coding RNA in breast cancer","volume":"29","author":"Xiang","year":"2024","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.canlet.2026.218727_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216247","article-title":"Non-coding RNAs in enzalutamide resistance of castration-resistant prostate cancer","author":"Gao","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218727_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2021.06.006","article-title":"Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance","volume":"518","author":"Jamroze","year":"2021","journal-title":"Cancer Lett."},{"issue":"11","key":"10.1016\/j.canlet.2026.218727_bib11","doi-asserted-by":"crossref","first-page":"469","DOI":"10.6004\/jnccn.2025.0052","article-title":"Prostate cancer, version 3.2026, NCCN clinical practice guidelines in oncology","volume":"23","author":"Spratt","year":"2025","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"20","key":"10.1016\/j.canlet.2026.218727_bib12","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.canlet.2026.218727_bib13","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/jamaoncol.2024.0591","article-title":"Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: a review","volume":"10","author":"Hussain","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2026.218727_bib14","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.canlet.2021.03.018","article-title":"Long non-coding RNAs in the doxorubicin resistance of cancer cells","volume":"508","author":"Ashrafizaveh","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218727_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2025.103689","article-title":"The crosstalk between glutathione metabolism and non-coding RNAs in cancer progression and treatment resistance","volume":"84","author":"Chang","year":"2025","journal-title":"Redox Biol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218727_bib16","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s12943-024-02145-1","article-title":"Overcoming multi-drug resistance in SCLC: a synergistic approach with venetoclax and hydroxychloroquine targeting the lncRNA LYPLAL1-DT\/BCL2\/BECN1 pathway","volume":"23","author":"Li","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2026.218727_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101111","article-title":"LncRNA DYNLRB2-AS1 promotes gemcitabine resistance of nasopharyngeal carcinoma by inhibiting the ubiquitination degradation of DHX9 protein","volume":"76","author":"Chen","year":"2024","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.canlet.2026.218727_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2019.109422","article-title":"LncRNA NEAT1 promotes docetaxel resistance in prostate cancer by regulating ACSL4 via sponging miR-34a-5p and miR-204-5p","volume":"65","author":"Jiang","year":"2020","journal-title":"Cell. Signal."},{"key":"10.1016\/j.canlet.2026.218727_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215829","article-title":"Docetaxel resistance-derived LINC01085 contributes to the immunotherapy of hormone-independent prostate cancer by activating the STING\/MAVS signaling pathway","volume":"545","author":"Zhang","year":"2022","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.canlet.2026.218727_bib20","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/s41374-022-00736-4","article-title":"Silencing of LINC01963 enhances the chemosensitivity of prostate cancer cells to docetaxel by targeting the miR-216b-5p\/TrkB axis","volume":"102","author":"Xing","year":"2022","journal-title":"Lab. Invest."},{"key":"10.1016\/j.canlet.2026.218727_bib21","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.canlet.2019.11.014","article-title":"FOXM1 contributes to docetaxel resistance in castration-resistant prostate cancer by inducing AMPK\/mTOR-mediated autophagy","volume":"469","author":"Lin","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218727_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101181","article-title":"5-methylcytosine methylation of MALAT1 promotes resistance to sorafenib in hepatocellular carcinoma through ELAVL1\/SLC7A11-mediated ferroptosis","author":"Shi","year":"2025","journal-title":"Drug Resist. Updates"},{"issue":"30","key":"10.1016\/j.canlet.2026.218727_bib23","article-title":"Targeting GPX4 to induce ferroptosis overcomes chemoresistance mediated by the PAX8-AS1\/GPX4 axis in intrahepatic cholangiocarcinoma","volume":"12","author":"Chen","year":"2025","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.canlet.2026.218727_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217503","article-title":"The YTHDF3-DT\/miR-301a-3p\/INHBA axis attenuates autophagy-dependent ferroptosis in lung adenocarcinoma","volume":"613","author":"Peng","year":"2025","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.canlet.2026.218727_bib25","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41580-023-00694-9","article-title":"Transcription regulation by long non-coding RNAs:mechanisms and disease relevance","volume":"25","author":"Ferrer","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"9","key":"10.1016\/j.canlet.2026.218727_bib26","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1136\/gutjnl-2021-324984","article-title":"RNA binding protein DDX5 directs tuft cell specification and function to regulate microbial repertoire and disease susceptibility in the intestine","volume":"71","author":"Long","year":"2022","journal-title":"Gut"},{"issue":"46","key":"10.1016\/j.canlet.2026.218727_bib27","article-title":"Increased PRP19 in hepatocyte impedes B cell function to promote hepatocarcinogenesis","volume":"11","author":"Liu","year":"2024","journal-title":"Adv. Sci. (Weinh.)"},{"issue":"12","key":"10.1016\/j.canlet.2026.218727_bib28","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1158\/1535-7163.MCT-19-0095","article-title":"LncRNA CCAT1 promotes prostate cancer cell proliferation by interacting with DDX5 and MIR-28-5P","volume":"18","author":"You","year":"2019","journal-title":"Mol. Cancer Therapeut."},{"issue":"41","key":"10.1016\/j.canlet.2026.218727_bib29","doi-asserted-by":"crossref","first-page":"20453","DOI":"10.1073\/pnas.1909047116","article-title":"DDX5 helicase resolves G-quadruplex and is involved in MYC gene transcriptional activation","volume":"116","author":"Wu","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.canlet.2026.218727_bib30","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3390\/genes15070841","article-title":"DDX5 can act as a transcription factor participating in the formation of chicken PGCs by targeting BMP4","volume":"15","author":"Zuo","year":"2024","journal-title":"Genes (Basel)"},{"issue":"5","key":"10.1016\/j.canlet.2026.218727_bib31","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.3390\/ijms25052836","article-title":"Integrated bioinformatics analysis identified ASNS and DDIT3 as the therapeutic target in Castrate- resistant prostate cancer","volume":"25","author":"Jung","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.canlet.2026.218727_bib32","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1111\/cas.16349","article-title":"Selective killing of castration-resistant prostate cancer cells by formycin A via the ATF4-CHOP axis","volume":"115","author":"Takei","year":"2024","journal-title":"Cancer Sci."},{"issue":"3","key":"10.1016\/j.canlet.2026.218727_bib33","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3892\/etm.2021.10429","article-title":"ChaC glutathione specific \u03b3-glutamylcyclotransferase 1 inhibits cell viability and increases the sensitivity of prostate cancer cells to docetaxel by inducing endoplasmic reticulum stress and ferroptosis","volume":"22","author":"He","year":"2021","journal-title":"Exp. Ther. Med."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352600491X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352600491X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T22:30:04Z","timestamp":1785969004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030438352600491X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":33,"alternative-id":["S030438352600491X"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218727","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel lncRNA HUDRPC suppresses ferroptosis via the DDX5\/DDIT3 pathway to promote docetaxel resistance in prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218727","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218727"}}